公开(公告)号：US11465994B2

公开(公告)日：2022-10-11

申请号：US16461427

申请日：2017-11-17

申请人： Takeda Pharmaceutical Company Limited

发明人： Martin Teall ,  Kathryn White ,  Stephen Mack ,  Gemma Liwicki ,  Anne Stephenson ,  Louise Dickson

IPC分类号： C07D413/04 ,  C07D311/68 ,  C07D401/12 ,  C07D401/14 ,  C07D407/04

摘要： The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.